Announcements Trials
Browse Landscape

Phase

Phase 1 133Phase 2 122Phase 1/2 64Phase EARLY_PHASE1 22Phase NA 21Phase 3 7Phase 4 6Phase 2/3 3

Status

Recruiting 3Not yet recruiting 2Unknown 1

Sponsor Class

OTHER 6OTHER_GOV 2INDUSTRY 2

Study Type

Interventional 6

Sponsor

Cancer Type

Lymphoid 6Myeloid 1

Conditions

Breast Neoplasms 208Neoplasms 130Polycystic Ovary Syndrome 107Carcinoma, Hepatocellular 82Colorectal Neoplasms 77Prostatic Neoplasms 70Stomach Neoplasms 55Lung Neoplasms 51Precursor Cell Lymphoblastic Leukemia-Lymphoma 49Carcinoma, Non-Small-Cell Lung 43Pain, Postoperative 42Pancreatic Neoplasms 41Head and Neck Neoplasms 38Pain 37Liver Neoplasms 36Leukemia, Myeloid, Acute 32Leiomyoma 32Keratosis, Actinic 31Colonic Neoplasms 31Recurrence 30Neoplasm Metastasis 29Multiple Myeloma 28Infertility 28Brain Neoplasms 28Uterine Cervical Neoplasms 26Urinary Bladder Neoplasms 24Ovarian Neoplasms 24Lymphoma 24Esophageal Neoplasms 23Obesity 22

Interventions

relmacabtagene autoleucel 2zanubrutinib 1axicabtagene ciloleucel 1Rituximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 4 × OTHER × Lymphoma, B-Cell × Clear all
NCT07270835 2025-12-08

Zanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell Lymphoma

The First Affiliated Hospital of Soochow University

Phase 4 Recruiting
40 enrolled
LymphoidMyeloid

Lymphoma, B-Cell, Lymphohistiocytosis, Hemophagocytic

NCT06956092 2025-05-02

Glofitamab

Zhengzhou University

Phase 4 Not yet recruiting
40 enrolled
Lymphoid

Lymphoma, B-Cell

NCT05806580 2024-10-23

Secondary Infusion of Relma-cel Injection for Relapsed or Refractory B-cell Lymphoma

Ruijin Hospital

Phase 4 Recruiting
8 enrolled
Lymphoid

Recurrence, Lymphoma, B-Cell

NCT06609304 2024-10-15

axi-cel

Zhengzhou University

Phase 4 Recruiting
20 enrolled
Lymphoid

Lymphoma, B-Cell

NCT05814848 2023-06-15

A Study of Secondary Infusion of Relmacabtagene Autoleucel Injection for Relapsed or Refractory B-cell Lymphoma

Changhai Hospital

Phase 4 Not yet recruiting
13 enrolled
Lymphoid

Recurrence, Lymphoma, B-Cell

NCT02992834 2016-12-14

Anti-CD19:TCRζ Chimeric Antigen Receptor-T Cells in the Treatment for CD19+ B Cell Lymphoma

The First People's Hospital of Changzhou

Phase 4 Unknown
10 enrolled
Lymphoid

Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡